文献速递药物相互作用特殊人群用药

囊性纤维化患者合用奈玛特韦-利托那韦时依来曲伐-替扎卡伐-依伐卡伐的PBPK指导

Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.
PubMed 文献 · Clin Pharmacol Ther · 2022-04-06

该研究针对囊性纤维化(CF)患者使用elexacaftor-tezacaftor-ivacaftor治疗COVID-19时与奈玛特韦-利托那韦的潜在药物相互作用,采用基于生理的药代动力学(PBPK)建模评估利托那韦对CFTR调节剂药代动力学的影响。模型预测利托那韦第1至5天给药后,第6天依伐卡伐的AUC比为9.31,提示其代谢被强烈抑制;据此建议合用期间调整剂量并延迟恢复全剂量。

要点

  • 利托那韦强烈抑制依伐卡伐代谢,预测第6天AUC比达9.31。
  • 合用奈玛特韦-利托那韦时,第1天和第5天应降低elexacaftor-tezacaftor-ivacaftor剂量。
  • 考虑利托那韦机制性抑制的残留效应,第9天再恢复全剂量。

核心结论

  • PBPK模型预测,CF患者合用奈玛特韦-利托那韦时需调整elexacaftor-tezacaftor-ivacaftor剂量以减轻药物相互作用影响。

研究设计与样本

  • 采用基于生理的药代动力学建模方法,纳入elexacaftor-tezacaftor-ivacaftor的生理信息和药物依赖性参数,并用独立临床药代动力学及DDI数据验证模型。

主要发现

  • 利托那韦第1至5天给药后,预测第6天依伐卡伐(最敏感的CYP3A底物)的AUC比为9.31,表明其代谢被强烈抑制。

关键数值与推荐

  • 合用奈玛特韦-利托那韦时,第1天和第5天应将elexacaftor-tezacaftor-ivacaftor剂量降至elexacaftor 200 mg-tezacaftor 100 mg-ivacaftor 150 mg。
  • 考虑利托那韦作为机制性抑制剂的残留抑制效应,第9天再恢复全剂量elexacaftor-tezacaftor-ivacaftor。

临床怎么用

  • 临床在为CF患者处方奈玛特韦-利托那韦治疗COVID-19时,应按模型预测方案调整elexacaftor-tezacaftor-ivacaftor剂量并延迟恢复全剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies, including elexacaftor-tezacaftor-ivacaftor, are primarily eliminated through cytochrome P450 (CYP) 3A-mediated metabolism. This creates a therapeutic challenge to the treatment of coronavirus disease 2019 (COVID-19) with nirmatrelvir-ritonavir in people with cystic fibrosis (CF) due to the potential for significant drug-drug interactions (DDIs). However, the population with CF is more at risk of serious illness following COVID-19 infection and hence it is important to manage the DDI risk and provide treatment options. CYP3A-mediated DDI of elexacaftor-tezacaftor-ivacaftor was evaluated using a physiologically-based pharmacokinetic modeling approach. Modeling was performed incorporating physiological information and drug-dependent parameters of elexacaftor-tezacaftor-ivacaftor to predict the effect of ritonavir (the CYP3A inhibiting component of the combination) on the pharmacokinetics of elexacaftor-tezacaftor-ivacaftor. The elexacaftor-tezacaftor-ivacaftor models were verified using independent clinical pharmacokinetic and DDI data of elexacaftor-tezacaftor-ivacaftor with a range of CYP3A modulators. When ritonavir was administered on Days 1 through 5, the predicted area under the curve (AUC) ratio of ivacaftor (the most sensitive CYP3A substrate) on Day 6 was 9.31, indicating that its metabolism was strongly inhibited. Based on the predicted DDI, the dose of elexacaftor-tezacaftor-ivacaftor should be reduced when coadministered with nirmatrelvir-ritonavir to elexacaftor 200 mg-tezacaftor 100 mg-ivacaftor 150 mg on Days 1 and 5, with delayed resumption of full-dose elexacaftor-tezacaftor-ivacaftor on Day 9, considering the residual inhibitory effect of ritonavir as a mechanism-based inhibitor. The simulation predicts a regimen of elexacaftor-tezacaftor-ivacaftor administered concomitantly with nirmatrelvir-ritonavir in people with CF that will likely decrease the impact of the drug interaction.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hong E, Almond LM, Chung PS, et al. Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19. Clin Pharmacol Ther. 2022. PMID: 35292968. doi:10.1002/cpt.2585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。